Dementia Translational Research Collaboration

A network of leading investigators in dementia

The NIHR Dementia Translational Research Collaboration (Dementia-TRC) aims to collaborate with industry, academia and charities in this field. It is open to developing partnerships with companies to carry out experimental medicine investigations in dementia and related diseases. 

The challenge of dementia 

Dementia is now the leading cause of death in the UK. It is the only condition in the top 10 causes of death without a treatment to prevent, cure or slow its progression. By 2025, the number of people with dementia in the UK is estimated to be over 1.1 million. This will cost the NHS tens of billions of pounds each year.

The need for working in an interdisciplinary and collaborative way is a key element to successfully address the global societal challenge of dementia.

Who we are

The NIHR Dementia Translational Research Collaboration is part of the UK government’s response to the growing challenge of Dementia. The Dementia-TRC comprises eight NIHR Biomedical Research Centres (BRCs) with dementia-related research themes and three Clinical Research Facilities (CRFs). These BRCs and CRFs are world-leaders in dementia translational research, based within top NHS-university partnerships.

Each centre is represented by an academic lead who acts as an advocate for the collaboration, provides scientific input into study design, and identifies and supports collaborative and business development activities.

The breadth of expertise in dementia in the UK

The map shows the locations of some of the key dementia centres based across the UK (listed below) which are part of this TRC.

List of Dementia TRC partner organisations

To find out more about the NIHR Dementia-TRC, our expertise, and how your company or organisation can collaborate with us, please contact the NIHR by email: 

What we can offer

Working together to further research and develop new treatments for dementia. 

With world-leading dementia expertise in experimental medicine and with access to state-of-the-art techniques and facilities, the Dementia-TRC offers huge synergies over and above its individual parts. 

The Dementia-TRC has world-class research programmes aimed at translating advances in discovery science into the clinic. As well as having a wealth of expertise, the Dementia-TRC can also provide access to patients from multiple sites across the UK.

Collectively, the Dementia-TRC provides significant opportunities to expand research capability and capacity, as well as providing a unique platform for the facilitation of collaboration and knowledge sharing with industry and the charity sector.

The Dementia-TRC also boasts a wealth of expertise in investigating novel technologies and devices, including in the wearables and AI fields, focussing on: 

  • biomarker discovery and validation
  • early diagnosis
  • patient stratification
  • phase I and phase II experimental medicine
  • proof of concept trials. 

It is open to collaborations with any life sciences company, including pharmaceutical and diagnostic companies, and academic institutions. It will consider fully-funded projects as well as projects that will look for third party funding.

To find out more about the NIHR Dementia-TRC, our expertise and how your company or organisation can collaborate with us, please contact the NIHR by email: 

Our expertise and strengths

The NIHR Dementia-TRC provides world-class expertise and capabilities covering every field related   to dementia, including:

  • Improving, aligning and streamlining imaging (including MRI and PET) techniques and processes;
  • Developing novel biomarkers to facilitate early and more effective diagnosis of neurodegenerative diseases;
  • Discovery, development and delivery of innovative disease-modifying therapies, which include those discovered through the longitudinal study of genetically at-risk cohorts;
  • Investigating novel technologies and devices, including in the wearables space, as tool for diagnosing, monitoring and treatment;
  • Extrapolation of discoveries in young-onset dementia to older patient groups;
  • Detection, prevention and treatment of protein misfolding and aggregation in dementia. 

The Dementia-TRC is also focused on developing the skills of researchers in the dementia space and enhancing the reputation of the dementia research landscape in the UK. 

The Dementia-TRC specialties include, but are not limited to:

  • Late-onset dementias, including Alzheimer’s disease, Vascular disease and Lewy body dementia
  • Young-onset dementias
  • Frontotemporal dementia with motor neuron disease
  • Parkinson’s disease, including progression to dementia
  • Neuroinflammation
  • Huntington’s disease

The Dementia-TRC regularly reviews areas of unmet need to determine emerging topics of focus for the group.

Contact us 

The NIHR Dementia-TRC provides a unique opportunity to collaborate with industry, academia, charities and the NHS to advance research.

To find out more about the NIHR Dementia-TRC, our expertise and how your company or organisation can collaborate with us, please contact the NIHR by email: 

Related pages

Latest news about Dementias and Neurodegeneration